Akers Biosciences Share Discussion Threads

[norbus] 11/12/2014 16:49

mcm

if you want the truth contact Tom, if you can't pop over for a drink as I did 2 years ago The money does not reckon China deal for the time being unleaa you have approval

continued Dr. Akers. "We have been working with NovoTek for two years to advance the regulatory approval process required to launch these tests into China. We are delighted that Akers' tests will be the first approved diagnostic assay in China to assist in the diagnosis of the allergy to the widely used blood-thinner, heparin."

Akers' tests will be : Perhaps when they ARE, the market will take more notice

[mcmather] 11/12/2014 09:46

Certainly wouldn't rule it out Norbus. However, this is from post 940 on here from 31 Dec 2012 re this Chinese agreement:

"I understand that it takes somewhere between 12-24 months to gain SFDA approval in China. The RNS stated "PIFA's entrance into Asia's largest market has already been received positively by Novotek's customer base through their pre-launch market research programs and Novatek has committed to funding the costs of obtaining State Food & Drug Administration ("SFDA") approval which will enable the product to be sold throughout China" - ie I don't think that there will be revenue here until late 2013 at the earliest?"

Here is the link to the original rns dated 26 Nov 2012:


Where we need to treat Dr Walt and his cosy mates with massive caution is when considering that the below commentary was also from that same post 940 31 DECEMBER 2012; since then Dr Walt has banked nearly $700k in salary - perhaps more with expenses? - and in Q3 2014 revenue was just $453,313 with losses in the quarter at $1,055,913; ie are investors here and in the US merely providers of Dr Walt's livelihood??

"Sales of PIFA Heparin/PF4 Rapid Assay seemed to have plateau'd - just a 5% increase in H1 2012 compared to H1 2011. However, the commercial availability of the PIFA PLUSS PF4 product line extension from Q3/Q4 2012 should hopefully assist here.

The company are expecting measurable sales activity during H2 2012 for the Breath Ketone device.

There is also reference to VIVO (seemingly the replacement for Revelar) and BreathScan PRO although no specific reference to either generating revenues in 2012."

[rivaldo] 11/12/2014 08:51

Finncap retain their Buy and 310p valuation following yesterday's contract news - but in their note they also have this little gem. Not bad for a £11m m/cap company with cash almost equating to the m/cap:

"Deal worth minima of US$67.2m.

NovoTek is Akers' distribution partner for PIFA Heparin PF4 and PIFA PLUSS PF4 in China. The agreement is for nine years following regulatory approval and contains contractual minima: $1m per annum in years one to three, $4.8m in years four and five, $11.5m in years six and seven, rising to $15.8m in years eight and nine".

[norbus] 10/12/2014 17:25

My point is China is exotic and mouthwateringly big market; But everyone knows things can go wrong, so a safe destination for a bit of busibess to announce; I could be miles out but have seen many a scam in and through china; Chinese love shares, and if the deal was serious the price would have rocketed

[mcmather] 10/12/2014 16:53

Indeed. I have been periodically checking Novotek's website and have noted some progress there (ie news / announcements / etc) of late which has provided a little confidence. However, also a little mindful of other 'practices' in the area:

The great Chinese fakeaway: How China's ripping off our iconic designs and flogging them for a fraction of the price.

[norbus] 10/12/2014 16:38

mcm
Try to manage your expectations is my advice; Do not trust business in China till you get the money in hand; such a deal buys a few months before a smell if any emerges , and can always be unravelled away. acting in the interest of AKR or Ray Mitty; A genuine deal with China would have seen the price double imo

[mcmather] 10/12/2014 16:22

Agree but Dr Mitty was previously alluding to Eddie Kendrick having hit the ground running, making waves, etc. However, the performance so far of Kendrick and his team has been pretty average and not really better than what has gone on before. If there is genuine and notable improvement there in Q4 then that might also slightly change sentiment re credibility of Dr Walt / the company.

[rivaldo] 10/12/2014 15:45

Q4 results as a whole are unimportant. No-one's expecting breakeven just yet. Of much more importance is that AKR are finally obtaining material contracts and orders, and that they're proving the business model.

Cash flow breakeven will come assuming they continue to do so - as you say, US sales would help in this regard! - in which case the current £11m m/cap would look nonsensical. Especially considering the extremely healthy Balance Sheet and cash pile.

[mcmather] 10/12/2014 14:06

The margin for the PIFA PF4/Heparin devices is over 50% I understand. That would still likely mean a loss for Q4 2014 unless Eddie Kendrick has got his act together with sales in the US?

[mcmather] 10/12/2014 10:56

Nothing on here yet but this is the English version of Novotek Therapeutics' website:

[algernon2] 10/12/2014 10:11

Some pre-Xmas cheer at last.
I'll drink to that.
Hic!

[rivaldo] 10/12/2014 10:08

From this morning's Times - good coverage (except that the m/cap is a little light, and the French breathalyser info is somewhat out of date....):

hxxp://www.thetimes.co.uk/tto/business/columnists/article4292892.ece

"Passing test with flying colours

In a dismal market, Akers Biosciences held firm. This is the £8.5 million New Jersey-based, AIM-quoted specialist in on-the-spot medical tests.

Last year, Akers became only the third supplier of portable breathalysers to be awarded the NF Mark, a French kitemark, in a country where every driver on its roads must carry a working, unused, disposable breathalyser. It is also developing a fast test to diagnose lung cancer via breath.

Its premium test, Heparin PF4 Rapid Assay, is on sale in the United States, where it helps to determine in minutes whether any patient being treated with the widely used blood-thinner is developing a potentially fatal allergic reaction. About 12 million patients there are given heparin every year and as many as 5 per cent develop an allergy.

Yesterday, there were whispers that Akers had received its first $1 million order for the same test from China. Unlike in the US, where there is a slower laboratory test for this allergy, China has no competing test and could become the second-biggest market for the product. Akers shares, 124p two years ago, as high as 690p a little over a year ago, marked time at 215p."

[mcmather] 10/12/2014 09:44

"We are delighted that Akers' tests will be the first approved diagnostic assay in China to assist in the diagnosis of the allergy to the widely used blood-thinner, heparin."

This is also separate to the J/V with Hainan Savy Investment Management Ltd and Mr Thomas Knox (eh?) to research, develop, produce and sell certain Akers' rapid diagnostic screening and testing products in China (the "Joint Venture").

[mcmather] 10/12/2014 09:34

Yeph, agree, though not before time.

[norbus] 10/12/2014 09:26

I hope you get paid and do not get disappointed

[rivaldo] 10/12/2014 07:13

Terrific news this morning of a $1m order from China - to be fulfilled this quarter - and this is just an "initial" order, with no competition whatsoever in the Chinese market and backing from the huge Novotek....

Plus AKR's m/cap is only £10.8m and is virtually covered by its cash pile.



"Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company"), a leading designer and manufacturer of rapid diagnostic screening and testing products, announces the receipt of an initial purchase order (the "Order") valued at US$1,000,000 from NovoTek Therapeutics Inc. ("NovoTek") to supply PIFA Heparin PF4/Rapid Assay products in Mainland China ("China").

NovoTek, a Beijing‐based pharmaceutical and medical device business development company, holds the exclusive sales and marketing rights for the Company's PIFA Heparin/PF4 Rapid Assay products in China. The Company expects to deliver the Order by December 31, 2014.

etc"

"NovoTek Therapeutics Inc. is a vital part of NovoTek Group, and is in charge of all international business. To date, NovoTek Group has grown to seven subsidiary companies focused on pharmaceutical marketing, medical and IVD products marketing, and contract research services. NovoTek has its own preclinical research facility, clinical trial and regulatory teams, and more than 600 sales representatives (500 for pharmaceuticals and 100 for medical devices) across China. NovoTek has more than 800 employees and more than 10 local branches nationwide. www.novotekchina.com "

[mcmather] 09/12/2014 23:40

I think the only fight that Dr Mitty is having is keeping his hand over his mouth to stop him from blurting more inaccuracies.

Just to recap, Dr Raymond Akers was suggesting for the most part of 2014 that the company bearing his name would be cash neutral by the end of 2014.

Net loss for Q1 2014 = $595,600
Net loss for H1 2014 = $1,090,595
Net loss for Q3 2014 = $1,055,913

The results for Q3 2014 specifically stating that "the Board is confident of a strong fourth quarter" (but subject to conditions / contingencies!?!). Notwithstanding Christmas Day, Boxing Day and weekends, there are now just 22 days left in Q4 / 2014 and not a whisper re any contracts / agreements / new deals / etc.

Tick-tock Dr Raymond Akers, investors in the UK and the US are watching and waiting.

[werewolfie] 09/12/2014 22:40

All quiet on the Akers front - they are based in Jersey arent they? Wonder if they are fighting a turf war with Tony Soprano for control of the "lucrative" disposable breathalyzer market?

[norbus] 01/12/2014 16:58

This thread is closed whilst the boss is finding out what Raymond Akers is up to

[mcmather] 27/11/2014 13:21

Despite Dr A's gibbering nonsense, the company is receiving a little bit of attention in the US:



3 Stocks Raising The Health Services Industry Higher

[mcmather] 27/11/2014 13:13

Think this is from today:

"Screening test and diagnostic-maker Akers Biosciences (AKR:AIM) could report its maiden pre-tax profit by 2016 with new product launches forecast to boost sales. Revenues are expected to show a 53% compound annual growth rate (CAGR) by 2017 from ... "


This just makes Dr Akers look like an absolute clown; all year he was saying that the company would be cash neutral by 2014. Now it is forecast that it "COULD report its maiden pre-tax profit" BY 2016!?

Dr Akers might be a scientist but, business wise, and I stress that this is my opinion from having been reviewing the company for the past 4/5 years or so, he appears to talk the most nonsense that I can recall having seen. He has claimed to be mates with Bill Clinton. And Walter Mitty I bet....

[norbus] 26/11/2014 08:26

hxxp://www.ineedmd.com/

Looks to have a place in any first aid kit

[mcmather] 25/11/2014 10:49

Interesting.

Everything in the Q3 results was Q4 will be strong, just you wait and see, etc. We are now nearly 2/3's of the way through Q4 but nothing re any news / contracts / etc. Tick-tock Dr Akers.

[norbus] 24/11/2014 12:15

Thomas Nicolette has a new job.
Now President and Chief Executive Officer at iNeedMD, Inc..